A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN MEN WITH OVERACTIVE BLADDER (OAB) SYMPTOMS WHILE TAKING THE ALPHA-BLOCKER TAMSULOSIN HYDROCHLORIDE FOR LOWER URINARY TRACT SYMPTOMS (LUTS) DUE TO BENIGN PROSTATIC HYPERPLASIA (BPH)

Registry ID

178-MA-1008

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE4

Study type

INTERVENTIONAL

Sponsor

ASTELLAS PHARMA GLOBAL DEVELOPMENT INC

Start date

2016-08-17

Completion date

2019-04-18

Last update

2016-04-21

Conditions

• PROSTATE HYPERPLASIA

View on source registry